Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities
The coronavirus disease 2019 (COVID-19) pandemic is caused by a newly emerged coronavirus (CoV) called Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). COVID-19 patients with cardiovascular disease (CVD) comorbidities have significantly increased morbidity and mortality. The use of angi...
- Autores:
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/13162
- Acceso en línea:
- https://www.sciencedirect.com/science/article/pii/S0163725820301583?via%3Dihub#!
http://hdl.handle.net/20.500.12010/13162
https://doi.org/10.1016/j.pharmthera.2020.107628
- Palabra clave:
- RAAS inhibitors
Hypertension
Bradykinin
Inflammation
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
- Rights
- License
- Acceso restringido
id |
UTADEO2_d93c78096826749c4f8ae01ea41b73a7 |
---|---|
oai_identifier_str |
oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/13162 |
network_acronym_str |
UTADEO2 |
network_name_str |
Expeditio: repositorio UTadeo |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities |
title |
Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities |
spellingShingle |
Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities RAAS inhibitors Hypertension Bradykinin Inflammation Síndrome respiratorio agudo grave COVID-19 SARS-CoV-2 Coronavirus |
title_short |
Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities |
title_full |
Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities |
title_fullStr |
Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities |
title_full_unstemmed |
Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities |
title_sort |
Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities |
dc.subject.spa.fl_str_mv |
RAAS inhibitors Hypertension Bradykinin Inflammation |
topic |
RAAS inhibitors Hypertension Bradykinin Inflammation Síndrome respiratorio agudo grave COVID-19 SARS-CoV-2 Coronavirus |
dc.subject.lemb.spa.fl_str_mv |
Síndrome respiratorio agudo grave COVID-19 SARS-CoV-2 Coronavirus |
description |
The coronavirus disease 2019 (COVID-19) pandemic is caused by a newly emerged coronavirus (CoV) called Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). COVID-19 patients with cardiovascular disease (CVD) comorbidities have significantly increased morbidity and mortality. The use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor type 1 blockers (ARBs) improve CVD outcomes; however, there is concern that they may worsen the prognosis of CVD patients that become infected with SARS-CoV-2 because the virus uses the ACE2 receptor to bind to and subsequently infect host cells. Thus, some health care providers and media sources have questioned the continued use of ACE inhibitors and ARBs. In this brief review, we discuss the effect of ACE inhibitor-induced bradykinin on the cardiovascular system, on the renin–angiotensin–aldosterone system (RAAS) regulation in COVID-19 patients, and analyze recent clinical studies regarding patients treated with RAAS inhibitors. We propose that the application of RAAS inhibitors for COVID-19 patients with CVDs may be beneficial rather than harmful. |
publishDate |
2020 |
dc.date.accessioned.none.fl_str_mv |
2020-09-11T15:19:29Z |
dc.date.available.none.fl_str_mv |
2020-09-11T15:19:29Z |
dc.date.created.none.fl_str_mv |
2020-05-09 |
dc.type.local.spa.fl_str_mv |
Artículo |
dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
format |
http://purl.org/coar/resource_type/c_6501 |
dc.identifier.issn.spa.fl_str_mv |
0163-7258 |
dc.identifier.other.spa.fl_str_mv |
https://www.sciencedirect.com/science/article/pii/S0163725820301583?via%3Dihub#! |
dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/20.500.12010/13162 |
dc.identifier.doi.spa.fl_str_mv |
https://doi.org/10.1016/j.pharmthera.2020.107628 |
identifier_str_mv |
0163-7258 |
url |
https://www.sciencedirect.com/science/article/pii/S0163725820301583?via%3Dihub#! http://hdl.handle.net/20.500.12010/13162 https://doi.org/10.1016/j.pharmthera.2020.107628 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_16ec |
dc.rights.local.spa.fl_str_mv |
Acceso restringido |
rights_invalid_str_mv |
Acceso restringido http://purl.org/coar/access_right/c_16ec |
dc.format.extent.spa.fl_str_mv |
9 páginas |
dc.format.mimetype.spa.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Pharmacology & Therapeutics |
dc.source.spa.fl_str_mv |
reponame:Expeditio Repositorio Institucional UJTL instname:Universidad de Bogotá Jorge Tadeo Lozano |
instname_str |
Universidad de Bogotá Jorge Tadeo Lozano |
institution |
Universidad de Bogotá Jorge Tadeo Lozano |
reponame_str |
Expeditio Repositorio Institucional UJTL |
collection |
Expeditio Repositorio Institucional UJTL |
bitstream.url.fl_str_mv |
https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13162/3/Good%20or%20bad%20Application%20of%20RAAS%20inhibitors%20in%20COVID-19%20patients%20with%20cardiovascular%20comorbidities.pdf https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13162/2/license.txt https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13162/4/Good%20or%20bad%20Application%20of%20RAAS%20inhibitors%20in%20COVID-19%20patients%20with%20cardiovascular%20comorbidities.png https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13162/5/Good%20or%20bad%20Application%20of%20RAAS%20inhibitors%20in%20COVID-19%20patients%20with%20cardiovascular%20comorbidities.pdf.jpg |
bitstream.checksum.fl_str_mv |
c54a461b3c942267773842c0f5c220b4 abceeb1c943c50d3343516f9dbfc110f 3c33bd14a529fb237a48e55516cbfa36 76a6e57d702143ef4af5100ab73df7fd |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio Institucional - Universidad Jorge Tadeo Lozano |
repository.mail.fl_str_mv |
expeditio@utadeo.edu.co |
_version_ |
1814213843783516160 |
spelling |
2020-09-11T15:19:29Z2020-09-11T15:19:29Z2020-05-090163-7258https://www.sciencedirect.com/science/article/pii/S0163725820301583?via%3Dihub#!http://hdl.handle.net/20.500.12010/13162https://doi.org/10.1016/j.pharmthera.2020.1076289 páginasapplication/pdfengPharmacology & Therapeuticsreponame:Expeditio Repositorio Institucional UJTLinstname:Universidad de Bogotá Jorge Tadeo LozanoRAAS inhibitorsHypertensionBradykininInflammationSíndrome respiratorio agudo graveCOVID-19SARS-CoV-2CoronavirusGood or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbiditiesArtículohttp://purl.org/coar/resource_type/c_6501Acceso restringidohttp://purl.org/coar/access_right/c_16ecThe coronavirus disease 2019 (COVID-19) pandemic is caused by a newly emerged coronavirus (CoV) called Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). COVID-19 patients with cardiovascular disease (CVD) comorbidities have significantly increased morbidity and mortality. The use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor type 1 blockers (ARBs) improve CVD outcomes; however, there is concern that they may worsen the prognosis of CVD patients that become infected with SARS-CoV-2 because the virus uses the ACE2 receptor to bind to and subsequently infect host cells. Thus, some health care providers and media sources have questioned the continued use of ACE inhibitors and ARBs. In this brief review, we discuss the effect of ACE inhibitor-induced bradykinin on the cardiovascular system, on the renin–angiotensin–aldosterone system (RAAS) regulation in COVID-19 patients, and analyze recent clinical studies regarding patients treated with RAAS inhibitors. We propose that the application of RAAS inhibitors for COVID-19 patients with CVDs may be beneficial rather than harmful.Wang, James JiqiEdin, Matthew L.Zeldin, Darryl C.Li, ChenzeWang, Dao WenChen, ChenORIGINALGood or bad Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.pdfGood or bad Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.pdfDocumento Reservadoapplication/pdf1047806https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13162/3/Good%20or%20bad%20Application%20of%20RAAS%20inhibitors%20in%20COVID-19%20patients%20with%20cardiovascular%20comorbidities.pdfc54a461b3c942267773842c0f5c220b4MD53embargoed access|||2420-09-11LICENSElicense.txtlicense.txttext/plain; charset=utf-82938https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13162/2/license.txtabceeb1c943c50d3343516f9dbfc110fMD52open accessTHUMBNAILGood or bad Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.pngGood or bad Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.pngimage/png135270https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13162/4/Good%20or%20bad%20Application%20of%20RAAS%20inhibitors%20in%20COVID-19%20patients%20with%20cardiovascular%20comorbidities.png3c33bd14a529fb237a48e55516cbfa36MD54open accessGood or bad Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.pdf.jpgGood or bad Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.pdf.jpgIM Thumbnailimage/jpeg19529https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/13162/5/Good%20or%20bad%20Application%20of%20RAAS%20inhibitors%20in%20COVID-19%20patients%20with%20cardiovascular%20comorbidities.pdf.jpg76a6e57d702143ef4af5100ab73df7fdMD55open access20.500.12010/13162oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/131622020-09-11 10:20:50.265embargoed access|||2420-09-11Repositorio Institucional - Universidad Jorge Tadeo Lozanoexpeditio@utadeo.edu.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 |